Number of patients at risk
194
194
148
111
112
66
81
45
18
6
233
243
171
150
128
89
97
53
46
25
6
3
0
0
0
1
Nivolumab
Docetaxel
292
290
Overall Survival: CheckMate-057
Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
20
2-year OS = 29%
2-year OS = 16%
Months
20
40
60
80
100
0
6
12
18
24
30
39
3
9
15
21
27
33
36
Nivolumab
Docetaxel
1-year OS = 51%
1-year OS = 39%
1
5
Δ12%
0
OS (%)
Δ13%
Events
Nivolumab
(n = 292)
n
Docetaxel
(n = 290)
n
Difference,
n
0−3 months
59
44
15
3−6 months
39
48
[9]
Peters S, et al. WCLC 2016
